Rättskällor med officiella primärkällor

Utskrivet ·

Skip to main content
Skip to the answer

Back to the decisions

Court of Justice of the European Union · Judgment

C-291/22 PDebregeas et associés Pharma (D & A Pharma) v European Commission and European Medicines Agency

Decided
2024-03-14
ECLI
ECLI:EU:C:2024:228
CELEX
62022CJ0291
Finality
Final, the decision cannot be appealed

The court's own keywords

Appeal – Medicinal products for human use – Application for marketing authorisation – Independence of experts consulted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) – Article 41 of the Charter of Fundamental Rights of the European Union – Right to good administration – Requirement of objective impartiality – Criteria for verifying the absence of conflict of interest – EMA’s policy on competing interests – Activities as a principal researcher, consultant or strategic adviser for the pharmaceutical industry – Rival products – Re-examination procedure – Regulation (EC) No 726/2004 – Article 56, Article 62, Article 63 – EMA Guidelines – Consultation of a scientific advisory group (SAG) or an ad hoc expert group.

Interprets

    Read from EU:s publikationsbyrå, Cellar (EUR-Lex och CURIA) on 2026-08-22.

    The row repeats what the source states. It is not a summary, not a conclusion about any single case and not legal advice.

    Verifiable trust signals

    • Six fixed blocks, one source per line
    • No sentence written by a language model
    • Engine version and read date on every answer
    • No customer data, no documents, no advice
    • Model card and audit published under the EU AI Act

    Model cardAudit